JPMorgan analyst Robbie Marcus raised his price target for Stryker to $215 from $200 and reiterates an Overweight rating on the shares. The analyst says that after a "bullish" management dinner, booth tour, and investor meeting, he's even more confident that Stryker can sustain its momentum for the balance of 2019 and a "healthy level" in 2020. The company exited 2018 in a position of strength following a year of peer-high organic growth and operating margin expansion despite meaningful acquisition dis-synergies, Marcus tells investors in a research note partially titled "There's Bullish, and Then There's Stryker's Messaging at AAOS."